ALCAR

FR0010907956

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:35:16 2025-02-14 am EST			Pre-market 02:26:01 am
0.9300 ^EUR	+1.97%		0.9650	+3.76%

01:48am	Carmat: positive publication in pulmonary hypertension	CF
01:48am	Carmat: positive publication in pulmonary hypertension	CF

Carmat SA authorizes a Buyback Plan.

December 22, 2024

The Board of Directors of Carmat SA has authorized a buyback plan on December 23, 2024.

Latest news about CARMAT

Carmat: positive publication in pulmonary hypertension	01:48am	CF
Carmat: positive publication in pulmonary hypertension	01:48am	CF
Carmat passes the 100-implant milestone for its artificial heart	Feb. 10	RE
Carmat: 100th Aeson implantation completed	Feb. 10	CF
Carmat: 100th Aeson implantation completed	Feb. 10	CF
Carmat Achieves Milestone Of 100 Implants Of Aeson Artificial Heart	Feb. 10	RE
CARMAT : Invest Securities slightly lowers its target	Feb. 04	CF
CARMAT : Invest Securities slightly lowers its target	Feb. 04	CF
Carmat: fundraising completed, with a 29% discount	Jan. 31	CF
Carmat raises 9.7 million euros in financing	Jan. 31	RE
CARMAT : Invest Securities upgrades to buy	Jan. 09	CF
CARMAT : Oddo BHF reduces its price target	Jan. 09	CF
Carmat: expects to double sales in 2025	Jan. 08	CF
Carmat plans to double its sales in 2025	Jan. 08	RE
Carmat Buys Back EUR2 Million Shares from Airbus Unit to Reduce Debt	Dec. 23	MT
Carmat: Airbus lowers its stake, debt is reduced	Dec. 23	CF
Tranche Update on Carmat SA's Equity Buyback Plan announced on December 23, 2024.	Dec. 23	CI
Carmat SA announces an Equity Buyback for 2,000,000 shares, for ?0.000001 million.	Dec. 23	CI
Carmat SA's Equity Buyback announced on December 23, 2024, has closed with 2,000,000 shares for ?0.000001 million.	Dec. 22	CI
Carmat SA authorizes a Buyback Plan.	Dec. 22	CI
Carmat: share price rises, scientific forum a success	Nov. 26	CF
Carmat: 30 heart transplants passed	Nov. 13	CF
Carmat passes 30 heart transplants for patients with its artificial heart	Nov. 13	RE
Carmat Provides an Update on Aeson® Artificial Heart?s Uptake as A Bridge to Transplant in Europe	Nov. 13	CI
Carmat Raises EUR10 Million via Public Offer	24-09-30	MT

CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.

Employees

162

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-04-23 - DGK Congress

More about the company